Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
The Many Facets of Cell Injury: Angiogenesis to Autophagy.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Depakote: No Prescription Cheap Low
Puma, but not noxa is essential for oligodendroglial cell death.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Dopaminergic Modulation of CD4+CD25 Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Fingolimod-A sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes.
[Infections and fingolimod].
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Calcitriol Modulates the CD46 Pathway in T Cells.
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
PI(3,5)P2 biosynthesis regulates oligodendrocyte differentiation by intrinsic and extrinsic mechanisms.

Pages